ClinicalTrials.gg
CompletedNCT02899988Updated Jun 18, 2020Results posted

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of Mirikizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 40 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
15th of 36
205 · median 181
Started
2016
with 4 others
Phase 2
9 of 36
none open now
Registered
17th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 15th largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 2, and was the 17th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • IL-23
  • dermatology
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the following criteria:

    • plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score ≥12 in affected skin at screening and baseline
    • sPGA score of ≥3 at screening and baseline
  • Candidate for biologic treatment for psoriasis.

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking product or could interfere with the interpretation of data.
  • Breastfeeding or nursing (lactating) women.
  • Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening.
  • Have received (s) (included attenuated live vaccines) within 1 month of screening or intend to during the study.
  • Have any other skin conditions (excluding psoriasis) that would affect interpretation of the results.
  • Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days prior to baseline.
  • Have received topical psoriasis treatment within 14 days prior to baseline.
  • Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17 targeting biologics within 8 weeks prior to baseline.
  • Have previous exposure to any biologic therapy targeting IL-23 (including ustekinumab), either licensed or investigational (previous briakinumab use is permitted).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    30 mg Mirikizumab

    30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).

    Drug: Mirikizumab

  • Experimental
    100 mg Mirikizumab

    100 mg Mirikizumab administered SC Q8W.

    Drug: Mirikizumab

  • Experimental
    300 mg Mirikizumab

    300 mg Mirikizumab administered SC Q8W.

    Drug: Mirikizumab

  • Placebo comparator
    Placebo

    Placebo administered SC Q8W.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3074828

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

    Time frame: Week 16

  2. Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

    Time frame: Week 16

  3. Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1

    The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.

    Time frame: Week 16

  4. Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score

    PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region \[United States/Outside United States (US/OUS)\], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.

    Time frame: Baseline, Week 16

  5. Mean Change (Improvement) From Baseline on the Patient Global Assessment

    The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.

    Time frame: Baseline, Week 16

  6. Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.

    Time frame: Baseline, Week 16

  7. Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 16

  8. Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104

    Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104

    Time frame: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 52, Week 56, Week 64, Week 72, Week 80, Week 88, Week 96, Week 100, Week 104

07

Results

Posted Jun 18, 2020

Participant flow

Induction Period (16 Weeks)
Participant flow — Induction Period (16 Weeks)
MilestoneInduction: PlaceboInduction: 30 mg Mirikizumab Q8WInduction:100 mg Mirikizumab Q8WInduction: 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRNMaintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRNMaintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNMaintenance: Placebo to 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8WMaintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8WMaintenance: 300 mg Mirikizumab Q8W
Started525151510000000
Received at least one dose of study drug525151510000000
Completed504951490000000
Not completed22020000000
Withdrew: Withdrawal by subject21000000000
Withdrew: Adverse event00020000000
Withdrew: Physician decision01000000000
Maintenance Period (88 Weeks)
Participant flow — Maintenance Period (88 Weeks)
MilestoneInduction: PlaceboInduction: 30 mg Mirikizumab Q8WInduction:100 mg Mirikizumab Q8WInduction: 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRNMaintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRNMaintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNMaintenance: Placebo to 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8WMaintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8WMaintenance: 300 mg Mirikizumab Q8W
Started000015303450342115
Rescue participants000100000000
Roll over to amah (nct03556202)00013918264224170
Completed000013273045301913
Not completed00002345422
Withdrew: Adverse event00001212221
Withdrew: Lost to follow-up00000101000
Withdrew: Withdrawal by subject00001032201
Follow-Up (16 Weeks)
Participant flow — Follow-Up (16 Weeks)
MilestoneInduction: PlaceboInduction: 30 mg Mirikizumab Q8WInduction:100 mg Mirikizumab Q8WInduction: 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRNMaintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRNMaintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNMaintenance: Placebo to 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8WMaintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8WMaintenance: 300 mg Mirikizumab Q8W
Started00002433620
Completed00002433620
Not completed00000000000

Outcome measures

PrimaryPercentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
percentage of participantsInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)0 (0 to 0)29.4 (16.9 to 41.9)58.8 (45.3 to 72.3)66.7 (53.7 to 79.6)
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Regression, Logistic · p = 0.009 · Risk difference (rd): 29.4 · 95% CI 16.9 to 41.9
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 58.8 · 95% CI 45.3 to 72.3
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 66.7 · 95% CI 53.7 to 79.6
SecondaryPercentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
percentage of participantsInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)0 (0 to 0)15.7 (5.7 to 25.7)31.4 (18.6 to 44.1)31.4 (18.6 to 44.1)
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Regression, Logistic · p = 0.039 · Risk difference (rd): 15.7 · 95% CI 5.7 to 25.7
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Regression, Logistic · p = 0.007 · Risk difference (rd): 31.4 · 95% CI 18.6 to 44.1
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Regression, Logistic · p = 0.007 · Risk difference (rd): 31.4 · 95% CI 18.6 to 44.1
SecondaryPercentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
percentage of participantsInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)3.8 (0 to 9.1)52.9 (39.2 to 66.6)78.4 (67.1 to 89.7)74.5 (62.5 to 86.5)
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 22.49 · 95% CI 5.62 to 89.97
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 74.6 · 95% CI 62.1 to 87.0
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 70.7 · 95% CI 57.6 to 83.7
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1

The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1
percentage of participantsInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
sPGA (0)0 (0 to 0)15.7 (5.7 to 25.7)31.4 (18.6 to 44.1)31.4 (18.6 to 44.1)
sPGA (0/1)1.9 (0 to 5.7)37.3 (24.0 to 50.5)70.6 (58.1 to 83.1)68.6 (55.9 to 81.4)
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Regression, Logistic · p = 0.041 · Risk difference (rd): 15.7 · 95% CI 5.7 to 25.7
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Regression, Logistic · p = 0.007 · Risk difference (rd): 31.4 · 95% CI 18.6 to 44.1
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Regression, Logistic · p = 0.008 · Risk difference (rd): 31.4 · 95% CI 18.6 to 44.1
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 35.3 · 95% CI 21.5 to 49.1
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 68.7 · 95% CI 55.6 to 81.7
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Regression, Logistic · p = <0.001 · Risk difference (rd): 66.7 · 95% CI 53.4 to 80.0
SecondaryMean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score

PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region \[United States/Outside United States (US/OUS)\], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score
units on a scaleInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score-4.35 ± 2.29-31.19 ± 2.34-42.33 ± 2.37-33.66 ± 2.27
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -26.84
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -37.99
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -29.32
SecondaryMean Change (Improvement) From Baseline on the Patient Global Assessment

The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Mean Change (Improvement) From Baseline on the Patient Global Assessment
units on a scaleInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Mean Change (Improvement) From Baseline on the Patient Global Assessment0.35 ± 0.162.24 ± 0.162.91 ± 0.162.82 ± 0.16
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.90
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): 2.56
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): 2.47
SecondaryMean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score

The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score
score on a scaleInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score-1.07 ± 0.69-9.19 ± 0.71-10.18 ± 0.69-9.64 ± 0.70
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -8.12
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -9.11
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · Mixed Models Analysis · p = <0.001 · Mean difference (net): -8.57
SecondaryMean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
score on a scaleInduction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg Mirikizumab
MCS0.28 ± 0.872.39 ± 0.902.74 ± 0.881.52 ± 0.88
PCS1.23 ± 0.844.58 ± 0.884.40 ± 0.855.09 ± 0.85
Statistical analysis
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · ANCOVA · p = 0.009 · Mean difference (net): 2.11
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · ANCOVA · p = 0.002 · Mean difference (net): 2.74
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · ANCOVA · p = 0.087 · Mean difference (net): 1.52
  • Induction: Placebo vs Induction: 30 mg Mirikizumab · ANCOVA · p = <0.001 · Mean difference (net): 3.35
  • Induction: Placebo vs Induction: 100 mg Mirikizumab · ANCOVA · p = <0.001 · Mean difference (net): 3.16
  • Induction: Placebo vs Induction: 300 mg Mirikizumab · ANCOVA · p = <0.001 · Mean difference (net): 3.86
SecondaryPharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104

Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104

Time frame:
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 52, Week 56, Week 64, Week 72, Week 80, Week 88, Week 96, Week 100, Week 104
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104
nanogram*hour per milliliter (ng*hr/mL)30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNPlacebo to 300 mg Mirikizumab Q8W30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W300 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 1043.22 ± 46.338.94 ± 79.1922.96 ± 55.8046.4 ± 62.834.83 ± 92.1347.66 ± 70.0851.30 ± 43.54

Adverse events

Collected over Up To 120 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction: Placebo0/52 (0%)1/52 (1.9%)19/52 (36.5%)
Induction: 30 mg Mirikizumab Q8W0/51 (0%)1/51 (2%)24/51 (47.1%)
Induction:100 mg Mirikizumab Q8W0/51 (0%)0/51 (0%)19/51 (37.3%)
Induction: 300 mg Mirikizumab Q8W0/51 (0%)1/51 (2%)19/51 (37.3%)
Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN0/15 (0%)1/15 (6.7%)13/15 (86.7%)
Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN0/30 (0%)2/30 (6.7%)20/30 (66.7%)
Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN0/34 (0%)1/34 (2.9%)23/34 (67.6%)
Maintenance: Placebo to 300 mg Mirikizumab Q8W0/50 (0%)2/50 (4%)38/50 (76%)
Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W0/34 (0%)2/34 (5.9%)28/34 (82.4%)
Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W0/21 (0%)2/21 (9.5%)18/21 (85.7%)
Maintenance: 300 mg Mirikizumab Q8W0/15 (0%)3/15 (20%)13/15 (86.7%)
300 mg Mirikizumab Q8W-Rescue0/10 (0%)1/10 (10%)9/10 (90%)
30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up0/2 (0%)0/2 (0%)0/2 (0%)
100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up0/4 (0%)0/4 (0%)1/4 (25%)
300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up0/3 (0%)0/3 (0%)0/3 (0%)
Placebo to 300 mg Mirikizumab Q8W-Follow-up0/3 (0%)0/3 (0%)0/3 (0%)
30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up0/6 (0%)0/6 (0%)2/6 (33.3%)
100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventInduction: PlaceboInduction: 30 mg Mirikizumab Q8WInduction:100 mg Mirikizumab Q8WInduction: 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRNMaintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRNMaintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNMaintenance: Placebo to 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8WMaintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8WMaintenance: 300 mg Mirikizumab Q8W300 mg Mirikizumab Q8W-Rescue30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-upPlacebo to 300 mg Mirikizumab Q8W-Follow-up30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/510/510/510/150/300/340/500/341/210/151/100/20/40/30/30/60/2
Atrial fibrillationCardiac disorders0/520/510/510/510/150/300/340/500/340/211/150/100/20/40/30/30/60/2
ErysipelasInfections and infestations0/520/510/510/510/150/300/340/500/340/211/150/100/20/40/30/30/60/2
PneumoniaInfections and infestations0/520/510/510/510/150/300/340/500/340/211/150/100/20/40/30/30/60/2
Cerebral haemorrhageNervous system disorders0/520/510/510/511/150/300/340/500/340/210/150/100/20/40/30/30/60/2
Femur fractureInjury, poisoning and procedural complications0/520/510/510/510/150/300/340/500/341/210/150/100/20/40/30/30/60/2
Endocarditis bacterialInfections and infestations0/520/510/510/510/151/300/340/500/340/210/150/100/20/40/30/30/60/2
Intraocular melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/510/510/510/151/300/340/500/340/210/150/100/20/40/30/30/60/2
Enlarged uvulaGastrointestinal disorders0/520/510/510/510/150/300/340/501/340/210/150/100/20/40/30/30/60/2
Pyelonephritis acuteInfections and infestations0/520/510/510/510/150/301/340/500/340/210/150/100/20/40/30/30/60/2
Most frequent other events
Showing 10 of 113
Most frequent other events
EventInduction: PlaceboInduction: 30 mg Mirikizumab Q8WInduction:100 mg Mirikizumab Q8WInduction: 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRNMaintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRNMaintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRNMaintenance: Placebo to 300 mg Mirikizumab Q8WMaintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8WMaintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8WMaintenance: 300 mg Mirikizumab Q8W300 mg Mirikizumab Q8W-Rescue30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-upPlacebo to 300 mg Mirikizumab Q8W-Follow-up30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up
InfluenzaInfections and infestations0/520/511/510/510/151/302/343/502/341/211/150/100/20/40/30/30/61/2
NasopharyngitisInfections and infestations7/525/516/518/513/153/307/3415/5012/345/215/152/100/20/40/30/30/60/2
Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/510/510/510/151/300/341/502/340/210/150/100/21/40/30/30/60/2
Upper respiratory tract infectionInfections and infestations2/526/513/512/512/155/302/348/503/345/211/151/100/20/40/30/30/60/2
HypertensionVascular disorders0/520/513/513/510/153/303/344/503/345/211/150/100/20/40/30/30/60/2
Back painMusculoskeletal and connective tissue disorders1/521/511/510/511/151/300/343/508/343/210/150/100/20/40/30/30/60/2
Injection site painGeneral disorders1/523/513/512/511/151/301/344/503/342/210/152/100/20/40/30/30/60/2
BronchitisInfections and infestations1/521/511/510/510/151/300/340/501/342/213/150/100/20/40/30/30/60/2
Ear infectionInfections and infestations0/520/510/510/510/150/300/340/500/340/210/150/100/20/40/30/31/60/2
PneumoniaInfections and infestations0/520/510/510/510/150/300/341/500/341/210/150/100/20/40/30/31/60/2

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Induction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg MirikizumabTotal
Mean46.0 ± 12.3949.2 ± 13.2846.0 ± 13.1847.5 ± 13.2347.2 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)Induction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg MirikizumabTotal
Female1012161553
Male42393536152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg MirikizumabTotal
Hispanic or Latino874524
Not Hispanic or Latino39374242160
Unknown or Not Reported575421
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg MirikizumabTotal
American Indian or Alaska Native00000
Asian677626
Native Hawaiian or Other Pacific Islander00000
Black or African American11338
White44434142170
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Induction: PlaceboInduction: 30 mg MirikizumabInduction: 100 mg MirikizumabInduction: 300 mg MirikizumabTotal
Canada477523
United States2120182382
Japan475420
Poland1914181465
Germany433515
08

Study locations

40 sites
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Dr. Shondra Smith MD
    Lake Charles, Louisiana 70605, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Calgary, T2G 1B1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Halifax, B3H1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H2K4L5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Peterborough, K9J 5K2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Richmond Hill, L4B 1A5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Waterloo, N2J 1C4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt am Main, 60590, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mahlow, 15831, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gifu, 501-1194, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kurume, 830-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morioka, 020-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagoya, 467-8602, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 545-8586, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shinagawa-KU, 141-8625, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shinjuku-ku, 169-0073, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Takaoka-shi, 9330871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tsu-shi, 514-8507, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-017, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-351, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-265, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Swidnik, 21-040, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 01-518, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 51-318, Poland
  • Grupo Dermatologico de Carolina
    Carolina, 00985, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2017, 9 months.

Results were first posted in Jun 2020, 2 years 11 months after primary completion. A results delay was requested in Jun 2018.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2016
First posted
Sep 14, 2016
StartActual
Sep 14, 2016
Primary completionActual
Jun 19, 2017
CompletionActual
May 8, 2019
Results delay requested
Jun 1, 2018
Results first posted
Jun 18, 2020
Last update
Jun 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02899988
Responsible party
Sponsor
First posted
Sep 14, 2016
Start date
Sep 14, 2016
Primary completion
Jun 19, 2017
Completion
May 8, 2019
Results posted
Jun 18, 2020
Last update
Jun 18, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion